England's National Institute of Health and Clinical Excellence (NICE) has published a Technology Appraisal on inhaled insulin.
Additionally, the Scottish Medicines Consortium (SMC) has rejected it for use on the NHS in Scotland.
The guidance recommends that Exubera is not routinely.
If certain specific criteria are met it is recommended that initiation and monitoring of treatment is carried out in a specialist centre and that treatment is only continued if there is evidence of clinically relevant improvements in glyclosylated haemaglobin (HbA1c).
Hat tip: Prescribing advice for GPs.
No comments:
Post a Comment